Reyon Pharmaceutical Co Ltd (102460) - Total Liabilities

Latest as of September 2025: ₩239.99 Billion KRW ≈ $162.63 Million USD

Based on the latest financial reports, Reyon Pharmaceutical Co Ltd (102460) has total liabilities worth ₩239.99 Billion KRW (≈ $162.63 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Reyon Pharmaceutical Co Ltd to assess how effectively this company generates cash.

Reyon Pharmaceutical Co Ltd - Total Liabilities Trend (2008–2024)

This chart illustrates how Reyon Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Reyon Pharmaceutical Co Ltd's assets to evaluate the company's liquid asset resilience ratio.

Reyon Pharmaceutical Co Ltd Competitors by Total Liabilities

The table below lists competitors of Reyon Pharmaceutical Co Ltd ranked by their total liabilities.

Company Country Total Liabilities
Lonyer Fuels
SHG:603003
China CN¥501.56 Million
Lu Thai Textile
SHE:200726
China HK$3.85 Billion
Texaf SA
BR:TEXF
Belgium €58.31 Million
Compañía Minera Autlán S.A.B. de C.V
MX:AUTLANB
Mexico MX$407.26 Million
Kolibri Global Energy Inc. Common stock
NASDAQ:KGEI
USA $80.89 Million
Atlas Lithium Corporation Common Stock
NASDAQ:ATLX
USA $35.17 Million
Manulife Holdings Bhd
KLSE:1058
Malaysia RM6.59 Billion

Liability Composition Analysis (2008–2024)

This chart breaks down Reyon Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Reyon Pharmaceutical Co Ltd (102460) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.60 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.03 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.51 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Reyon Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Reyon Pharmaceutical Co Ltd (2008–2024)

The table below shows the annual total liabilities of Reyon Pharmaceutical Co Ltd from 2008 to 2024.

Year Total Liabilities Change
2024-12-31 ₩250.05 Billion
≈ $169.46 Million
-0.44%
2023-12-31 ₩251.15 Billion
≈ $170.20 Million
+6.00%
2022-12-31 ₩236.93 Billion
≈ $160.56 Million
+1.80%
2021-12-31 ₩232.74 Billion
≈ $157.73 Million
+165.93%
2020-12-31 ₩87.52 Billion
≈ $59.31 Million
+67.69%
2019-12-31 ₩52.19 Billion
≈ $35.37 Million
-32.90%
2018-12-31 ₩77.77 Billion
≈ $52.71 Million
+9.27%
2017-12-31 ₩71.18 Billion
≈ $48.24 Million
+133.83%
2016-12-31 ₩30.44 Billion
≈ $20.63 Million
-0.42%
2012-12-31 ₩30.57 Billion
≈ $20.72 Million
+6.39%
2011-12-31 ₩28.73 Billion
≈ $19.47 Million
+29.70%
2009-12-31 ₩22.15 Billion
≈ $15.01 Million
-2.14%
2008-12-31 ₩22.64 Billion
≈ $15.34 Million
--

About Reyon Pharmaceutical Co Ltd

KO:102460 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$134.11 Million
₩197.90 Billion KRW
Market Cap Rank
#18062 Global
#887 in Korea
Share Price
₩10790.00
Change (1 day)
-3.66%
52-Week Range
₩9880.00 - ₩13750.00
All Time High
₩70413.22
About

REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough … Read more